Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 939 Shares of Stock

Key Points

• LeMaitre Vascular, Inc. Director John A. Roush sold 939 shares of stock at an average price of $93.49, resulting in a total transaction of $87,787.11 and a 24.36% decrease in his position.
• The company reported $0.60 EPS for the last quarter, exceeding analyst expectations by $0.03, alongside a 15% year-over-year revenue growth to $63.15 million.
• LeMaitre Vascular declared a quarterly dividend of $0.20, with a yield of 0.8%, scheduled for payment on September 4th.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director John A. Roush sold 939 shares of the firm's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $93.49, for a total transaction of $87,787.11. Following the transaction, the director owned 2,916 shares in the company, valued at $272,616.84. This represents a 24.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

LeMaitre Vascular Stock Performance

LMAT traded up $0.78 during trading on Wednesday, hitting $95.16. The stock had a trading volume of 21,578 shares, compared to its average volume of 188,963. The firm has a market cap of $2.15 billion, a PE ratio of 46.24, a P/E/G ratio of 2.38 and a beta of 0.79. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The company has a 50 day simple moving average of $83.82 and a 200-day simple moving average of $86.52.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business's quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.52 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LMAT shares. Cantor Fitzgerald lifted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a report on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of "Hold" and an average target price of $98.00.

Institutional Trading of LeMaitre Vascular

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its position in LeMaitre Vascular by 3.0% in the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after purchasing an additional 3,248 shares during the last quarter. Invesco Ltd. grew its position in LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Compass Planning Associates Inc grew its position in LeMaitre Vascular by 91.4% in the 1st quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock worth $988,000 after purchasing an additional 5,623 shares during the last quarter. Johnson Investment Counsel Inc. grew its position in LeMaitre Vascular by 34.8% in the 1st quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock worth $2,469,000 after purchasing an additional 7,603 shares during the last quarter. Finally, Consolidated Planning Corp acquired a new stake in LeMaitre Vascular in the 1st quarter worth $947,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.